Efficacy of tea catechin-rich beverages to reduce abdominal adiposity and metabolic syndrome risks in obese and overweight subjects: a pooled analysis of 6 human trials.
This post hoc pooled analysis assessed the effectiveness of green tea catechins (GTC) to reduce the risk of metabolic syndrome (MetS) associated with abdominal fat reduction, because previous findings are unclear. Data were pooled from six human trials (n=921, 505 men) comparing the effects of GTC-containing beverages (540-588 mg GTC/beverage) and a placebo beverage. Outcome measures were abdominal fat [total fat area (TFA), visceral fat area (VFA), subcutaneous fat area (SFA)], and MetS risk. We estimated mean changes from baseline and calculated confidence intervals (CI) to assess reductions in abdominal fat accumulation and MetS improvement. Subclass analyses were performed by classifying subjects as Pre-MetS or MetS at trial initiation. Additional subclass analyses were performed with Pre-MetS and MetS subjects further stratified according to whether GTC intake reduced TFA, VFA, or SFA. Consumption of GTC-containing beverages for 12 weeks significantly reduced TFA (-17.7cm2, 95%CI: -20.9 to -14.4), VFA (-7.5cm2, 95%CI: -9.3 to -5.7), SFA (-10.2cm2, 95%CI: -12.5 to -7.8), body weight, body mass index, and waist circumference; and improved blood pressure. Subclass analyses of Pre-MetS and MetS subjects showed improved MetS in the GTC group [odds ratio (OR), 1.67; 95%CI: 1.08-2.57]. The ORs for improved MetS in the TFA- and VFA-reduced groups were 2.79 (95%CI: 1.28-6.09) and 4.36 (95%CI: 2.03-9.39), respectively. Continual consumption of GTC-containing beverages reduced abdominal fat and improved MetS, suggesting its potential to prevent diabetes and cardiovascular disease. Additional large-scale intervention trials are needed to evaluate the effects of GTC on the risk of MetS in high-risk populations.